Cannabis can interfere with common medications like warfarin, clobazam, and opioids, leading to dangerous side effects. Learn which drug interactions are high-risk, how to stay safe, and what to do if you're already using both.
Learn how to safely report manufacturing quality issues without fear of retaliation. Understand your legal rights under CPSIA, FSMA, and MAP-21, deadlines, how to document claims, and what to do if you face retaliation.
Learn how to finish your antibiotic course and dispose of unused pills safely to fight antibiotic resistance. Simple steps for home care that protect you and your community.
Menopause hormone therapy can relieve severe symptoms and protect bone health-but risks like breast cancer and blood clots vary by age, type, and timing. Learn what's safe, what's not, and how to decide if it's right for you.
Learn how to effectively communicate about medication side effects with your doctor. Track symptoms, use proven communication tools, and know when to speak up-because your voice can prevent serious health risks.
Medications like antidepressants, cancer drugs, and stimulants can cause severe sweating and hot flashes. Learn proven, science-backed ways to manage these side effects without quitting your treatment.
Nitrosamine contamination in generic drugs has led to over 500 FDA recalls since 2018. Learn which medications were affected, how regulators responded, and what patients should know about safety and compliance.
Grapefruit juice can dangerously increase simvastatin levels in your blood, raising the risk of muscle damage and kidney failure. Learn how much is unsafe, which statins are safer, and what to do if you're currently taking simvastatin.
Therapeutic Equivalence Codes (TE Codes) tell you if a generic drug is a safe, FDA-approved swap for the brand-name version. Learn how they work, why they save money, and when to question a switch.
Biologic patent protection in the U.S. delays biosimilar entry for 12 years, costing patients billions. Learn how the BPCIA, patent thickets, and high development costs block competition-and why biosimilars still haven’t reached most patients.
